^
No biomarker
NSCLC
durvalumab + CP-675206
Sensitive
:
B
AstraZeneca Press Release - 4d
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive
:
A1
European Pharmaceutical Review - 4d
EGFR L858R
NSCLC
osimertinib
Sensitive
:
A1
European Pharmaceutical Review - 4d
STRN-ALK fusion
NSCLC
crizotinib
Sensitive
:
C4
Thorac Cancer - 4d
EGFR exon 19 deletion + T790M + C797S + HER-2 amplification
LUAD
afatinib + rivoceranib
Sensitive
:
C4
Onco Targets Ther - 4d
STRN-ALK fusion
NSCLC
alectinib
Resistant
:
C4
Thorac Cancer - 4d
EGFR mutation
NSCLC
EGFR inhibitor
Sensitive
:
A2
Oncol Res Treat - 6d
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive
:
A1
Roche Press Release - 6d
EGFR exon 20 insertion
NSCLC
TAK-788
Sensitive
:
B
Takeda Press Release - 1wk
EGFR T790M + C797S
LUAD
gefitinib + osimertinib
Resistant
:
C4
Onco Targets Ther - 1wk
EGFR T790M + C797S
LUAD
osimertinib + anlotinib
Sensitive
:
C4
Onco Targets Ther - 1wk
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
EGFR mutation
NSCLC
osimertinib
Sensitive
:
A2
Asia Pac J Clin Oncol - 2wk
ALK positive
NSCLC
brigatinib
Sensitive
:
A1
Expert Rev Anticancer Ther - 2wk
ROS1 fusion
NSCLC
entrectinib
Sensitive
:
A1
ESMO Open - 2wk
EGFR G719A
NSCLC
dacomitinib
Sensitive
:
C2
J Clin Oncol - 2wk
CALR elevation
NSCLC
docetaxel
Sensitive
:
C3
Lung Cancer - 2wk
CALR elevation
NSCLC
pemetrexed
Sensitive
:
C3
Lung Cancer - 2wk
CALR elevation + EGFR mutation
NSCLC
osimertinib
Sensitive
:
C3
Lung Cancer - 2wk
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive
:
A2
J Clin Oncol - 3wk
EGFR mutation
NSCLC
erlotinib + ramucirumab
Sensitive
:
A2
Cancer Treat Res Commun - 3wk
EGFR mutation
NSCLC
pembrolizumab
Sensitive
:
A1
Front Oncol - 3wk
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive
:
A1
JTO Clin Res Rep - 3wk
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive
:
A1
JTO Clin Res Rep - 3wk
EGFR mutation
NSCLC
bevacizumab
Sensitive
:
A2
J Formos Med Assoc - 3wk
EGFR L858R
NSCLC
bevacizumab
Sensitive
:
C2
J Formos Med Assoc - 3wk
OLR1 overexpression
NSCLC
Immunotherapy
Sensitive
:
C3
Front Oncol - 3wk
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive
:
C3
Lung Cancer - 3wk
BRAF mutation
NSCLC
PD-L1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
EGFR exon 19 deletion
NSCLC
EGFR inhibitor
Sensitive
:
C3
Future Oncol - 3wk
BRAF mutation
NSCLC
PD1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
XAGE1 antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
CTAG1B antibody elevation + XAGE1 antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
CTAG1B antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
HER-2 amplification
LUAD
pembrolizumab
Sensitive
:
C4
Front Oncol - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
camrelizumab
Resistant
:
C4
BMC Pulm Med - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
larotrectinib
Sensitive
:
C4
BMC Pulm Med - 3wk
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive
:
A1
No biomarker
NSCLC
ramucirumab
Sensitive
:
A1
ALK positive
NSCLC
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive
:
A1
EGFR L858R
NSCLC
afatinib
Sensitive
:
A1
EGFR T790M
NSCLC
osimertinib
Sensitive
:
A1
No biomarker
NSCLC
durvalumab
Sensitive
:
A1
ALK positive
NSCLC
alectinib
Sensitive
:
A1
PD-L1 expression
NSCLC
pembrolizumab
Sensitive
:
A1
ALK fusion
NSCLC
brigatinib
Sensitive
:
A1
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive
:
A1
MET exon 14 mutation
NSCLC
tepotinib
Sensitive
:
A1
No biomarker
NSCLC
bevacizumab
Sensitive
:
A1
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
NSCLC
dacomitinib
Sensitive
:
A1
EGFR T790M
NSCLC
lazertinib
Sensitive
:
A1
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive
:
A1
MET exon 14 mutation
NSCLC
capmatinib
Sensitive
:
A1
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive
:
A1
RET fusion
NSCLC
pralsetinib
Sensitive
:
A1
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
NSCLC
DP
Sensitive
:
A1
EGFR mutation
NSCLC
gefitinib
Sensitive
:
A1
EGFR L858R
NSCLC
gefitinib
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our